HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: So far it has been shown that suppression of histone deacetylase and phosphoinositide 3-kinase simultaneously worked better than single HDAC inhibitor for the treatment of cutaneous T-cell lymphoma or other cancers39,40.